Hermes Vector

Health

Experimental drug ERAS-0015 shows early results in pancreatic cancer trial

Erasca reported that 44 per cent of 25 patients with advanced pancreatic cancer saw tumours shrink substantially after taking a 32 mg daily dose of ERAS-0015 in an early-stage trial.

By Hermes Vector

Checked against 2 sourcesbnnbloomberg.cactvnews.ca
Illustration for: Experimental drug ERAS-0015 shows early results in pancreatic cancer trial

In brief

  • Erasca reported 44 per cent of 25 pancreatic cancer patients saw tumours shrink substantially on a 32 mg daily dose of ERAS-0015.
  • 69 per cent of patients with the two most common pancreatic cancer genetic variations experienced positive results.
  • Late-stage trials for ERAS-0015 and ERAS-4001 are planned to begin in 2027.
  • One patient taking a 24 mg dose previously died from lung inflammation, according to the company.

Experimental drug ERAS-0015 shows early results in pancreatic cancer trial

An experimental U.S. drug produced positive early results in patients with advanced pancreatic and lung cancers, according to Erasca, a San Diego-based drugmaker.

Trial results

Erasca reported that 44 per cent of 25 patients with pancreatic cancer saw tumours shrink substantially after taking a 32 mg daily dose of the pill ERAS-0015. Additionally, 69 per cent of patients with the two most common genetic variations of pancreatic cancer experienced positive results. For lung cancer, tumours diminished in three of five patients (60 per cent) who had previously received immunotherapy and chemotherapy.

The company said it would begin late-stage clinical trials to test ERAS-0015 and another experimental treatment called ERAS-4001 in 2027.

Expert reaction

Dr. Jennifer Knox, staff medical oncologist at the University Health Network’s Princess Margaret Cancer Centre in Toronto, will supervise patients when the trial comes to Canada next year as part of the global tests.

"It’s the biggest breakthrough for pancreas cancer probably ever," Knox said in a phone interview with CTVNews.ca on Friday. "It’s one of the biggest breakthroughs for cancer in general in recent years."

Knox noted the early-stage trial involved a small number of patients, which she described as "typical" at that phase. She expects a large number of people to participate in the upcoming clinical trial in Canada.

Dr. Sam Godfrey with Cancer Research UK said those receiving treatment for pancreatic cancer normally have less than a year to live.

"Now, that doesn’t mean that cancer’s completely gone… because sometimes microscopic cells remain and they come back, and that’s why we need longer trials," he said. "But the fact that we’re able to do this and we’re able to target something that previously was never targetable, that is a big science win."

Safety and context

Erasca CEO Dr. Jonathan Lim said in a press release that the new treatment was "generally well tolerated." The company had previously reported that one patient taking a 24 mg dose of the drug had died from lung inflammation.

Knox said the first breakthrough targeting the mutant RAS protein, present in around 95 per cent of pancreatic cancers, occurred earlier this year with the medication daraxonrasib from Revolution Medicines, which had doubled survival time in a clinical trial according to a U.S.-led study published in The New England Journal of Medicine in May. She said Erasca’s drug is similar to daraxonrasib, which is now licensed in the U.S.

Doctors say RAS proteins are like "on-off" switches for cell growth and can be harmful if they remain in the "on" mode when they mutate. The new experimental pill ERAS-0015 appears to prevent cancers from developing by blocking mutant RAS proteins that otherwise could allow cancer cells to multiply.


Sources

This article was drafted with AI assistance and checked against the sources above. Company claims are reported as claims. Cover image is AI-generated.

Questions readers ask

What were the early trial results for the experimental drug ERAS-0015?
Erasca reported that 44 per cent of 25 patients with pancreatic cancer saw tumours shrink substantially after taking a 32 mg daily dose of the pill. Additionally, 69 per cent of patients with the two most common genetic variations of pancreatic cancer experienced positive results.
When will late-stage clinical trials for ERAS-0015 begin?
The company said it would begin late-stage clinical trials to test ERAS-0015 and another experimental treatment called ERAS-4001 in 2027.
How does the drug ERAS-0015 work to treat cancer?
The new experimental pill ERAS-0015 appears to prevent cancers from developing by blocking mutant RAS proteins that otherwise could allow cancer cells to multiply.
What safety concerns have been reported regarding the drug?
Erasca CEO Dr. Jonathan Lim said in a press release that the new treatment was generally well tolerated, but the company had previously reported that one patient taking a 24 mg dose of the drug had died from lung inflammation.

The day's checked news, by email

One short email a day with the top stories. Free, and you can unsubscribe in one click.

Or follow for the latest news:

How do you feel about this story?

Comments 0

No comments yet. Start the discussion.

Health

Cambodia confirms first mpox case after 30-month absence

Cambodia's Ministry of Health reported one confirmed mpox case on November 22, 2026, the first since the country recorded no cases for 30 months and six days. The patient is receiving hospital treatment.

Checked against 2 sourceschinanews.com.cnthestar.com.my